

B1 a second DNA segment operably linked to the first DNA sequence, the second DNA sequence encoding a heterologous glycoprotein, wherein the heterologous glycoprotein is an immunoadhesin.

B2 5. (Amended) The DNA construct of claim [1] 2 wherein the DNA encoding the mammalian t-PA pro-sequence is operably linked to a pre-sequence other than a mammalian t-PA pre-sequence.

B3 7. (Amended) The DNA construct of claim [6] 5 wherein the immunoadhesin is a TNF receptor immunoadhesin.

B4 9. (Amended) The DNA construct of claim 5 wherein the mammalian t-PA pro-sequence is operably linked to a pre-sequence associated with the native heterologous polypeptide.

B5 ^{SUB D1} 14. (Amended) A DNA construct comprising a first DNA segment encoding a precursor polypeptide; and a second DNA segment operably linked to the first DNA [sequence] segment, the second DNA [sequence] segment, encoding a heterologous glycosylation site variant glycoprotein

B6 ^{SUB D2} 30. (Amended) A cultured eukaryotic host cell comprising a DNA construct comprising: a first DNA segment encoding a precursor peptide corresponding to a mammalian tissue plasminogen activator secretory peptide; and a second DNA segment operably linked to the first DNA [sequence] segment, the second DNA [sequence] segment encoding a heterologous glycosylation site variant.

Please add and consider new claims 34-46.

B7 ~~34~~ (New) A DNA construct comprising a first DNA segment comprising a nucleic acid sequence that encodes mammalian t-PA pro-sequence operatively linked to a nucleic acid sequence that encodes a pre-sequence other than a mammalian t-PA pre-sequence; and a second

DNA segment operably linked to the first DNA segment, wherein the second DNA segment encodes a heterologous glycoprotein.

~~2~~ 35. (New) The DNA construct of claim ~~34~~¹, wherein the heterologous glycoprotein is an immunoadhesin.

~~3~~ 36. (New) The DNA construct of claim ~~35~~², wherein the immunoadhesin is a TNF receptor immunoadhesin.

~~4~~ 37. (New) The DNA construct of claim ~~36~~³, wherein the TNF receptor immunoadhesin is TNFR1-IgG1.

~~5~~ 38. (New) The DNA construct of claim ~~34~~⁵, wherein the heterologous glycoprotein is a glycosylation site variant glycoprotein.

~~6~~ 39. (New) The DNA construct of claim ~~34~~¹, wherein the mammalian t-PA pro-sequence is operably linked to a pre-sequence associated with the native heterologous polypeptide.

~~7~~ 40. (New) The DNA construct of claim ~~39~~⁶, wherein the heterologous glycoprotein is a TNF receptor immunoadhesin and the pre-sequence is a pre-sequence of a mammalian TNF receptor.

~~8~~ 41. (New) The DNA construct of claim ~~40~~⁷, wherein the mammalian t-PA pro-sequence is SEQ ID NO. 7.

~~9~~ 42. (New) The DNA construct of claim ~~41~~⁸, wherein the pre-sequence is SEQ ID NO. 8.

~~10~~ 43. (New) The DNA construct of claim ~~42~~⁹, wherein the TNF receptor immunoadhesin is TNFR1-IgG1.